AU636944B2 - Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens - Google Patents
Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogensInfo
- Publication number
- AU636944B2 AU636944B2 AU69055/91A AU6905591A AU636944B2 AU 636944 B2 AU636944 B2 AU 636944B2 AU 69055/91 A AU69055/91 A AU 69055/91A AU 6905591 A AU6905591 A AU 6905591A AU 636944 B2 AU636944 B2 AU 636944B2
- Authority
- AU
- Australia
- Prior art keywords
- hiv
- recombinant
- particles
- gene
- nonreplicating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000002245 particle Substances 0.000 title claims description 349
- 230000001177 retroviral effect Effects 0.000 title claims description 54
- 239000003443 antiviral agent Substances 0.000 title description 5
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 333
- 210000004027 cell Anatomy 0.000 claims description 291
- 208000031886 HIV Infections Diseases 0.000 claims description 258
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 256
- 238000000034 method Methods 0.000 claims description 98
- 108090000623 proteins and genes Proteins 0.000 claims description 98
- 239000013612 plasmid Substances 0.000 claims description 85
- 241000700618 Vaccinia virus Species 0.000 claims description 81
- 101710091045 Envelope protein Proteins 0.000 claims description 57
- 101710188315 Protein X Proteins 0.000 claims description 57
- 102000004169 proteins and genes Human genes 0.000 claims description 49
- 108700004025 env Genes Proteins 0.000 claims description 48
- 101710205625 Capsid protein p24 Proteins 0.000 claims description 47
- 101710177166 Phosphoprotein Proteins 0.000 claims description 47
- 101710149279 Small delta antigen Proteins 0.000 claims description 47
- 208000015181 infectious disease Diseases 0.000 claims description 46
- 239000013598 vector Substances 0.000 claims description 45
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 44
- 239000001963 growth medium Substances 0.000 claims description 44
- 101150030339 env gene Proteins 0.000 claims description 36
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 claims description 34
- 101710132601 Capsid protein Proteins 0.000 claims description 32
- 108700004026 gag Genes Proteins 0.000 claims description 32
- 208000030507 AIDS Diseases 0.000 claims description 30
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 30
- 230000002163 immunogen Effects 0.000 claims description 26
- 241001430294 unidentified retrovirus Species 0.000 claims description 25
- 101150098622 gag gene Proteins 0.000 claims description 24
- 101710149951 Protein Tat Proteins 0.000 claims description 21
- 238000001890 transfection Methods 0.000 claims description 21
- 101710172711 Structural protein Proteins 0.000 claims description 18
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims description 16
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 210000004962 mammalian cell Anatomy 0.000 claims description 15
- 108020004414 DNA Proteins 0.000 claims description 14
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 claims description 13
- 108091005804 Peptidases Proteins 0.000 claims description 13
- 108010010369 HIV Protease Proteins 0.000 claims description 11
- 210000004970 cd4 cell Anatomy 0.000 claims description 11
- 101710149136 Protein Vpr Proteins 0.000 claims description 9
- 101710201961 Virion infectivity factor Proteins 0.000 claims description 9
- 210000004698 lymphocyte Anatomy 0.000 claims description 9
- 239000004365 Protease Substances 0.000 claims description 8
- 239000013603 viral vector Substances 0.000 claims description 8
- -1 rev Proteins 0.000 claims description 7
- 230000009385 viral infection Effects 0.000 claims description 7
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims description 3
- 208000008771 Lymphadenopathy Diseases 0.000 claims description 2
- 208000005074 Retroviridae Infections Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000018555 lymphatic system disease Diseases 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 16
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 claims 13
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 claims 4
- 108010016191 Human immunodeficiency virus 2 p16 protease Proteins 0.000 claims 4
- 208000005599 HTLV-I Infections Diseases 0.000 claims 2
- 206010001513 AIDS related complex Diseases 0.000 claims 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 1
- 208000007687 HTLV-II Infections Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 1
- 102000006240 membrane receptors Human genes 0.000 claims 1
- 230000014509 gene expression Effects 0.000 description 72
- 241000700605 Viruses Species 0.000 description 68
- 102100034349 Integrase Human genes 0.000 description 49
- 239000000427 antigen Substances 0.000 description 46
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 45
- 108091007433 antigens Proteins 0.000 description 44
- 102000036639 antigens Human genes 0.000 description 44
- 235000018102 proteins Nutrition 0.000 description 44
- 101710177291 Gag polyprotein Proteins 0.000 description 40
- 108010078428 env Gene Products Proteins 0.000 description 40
- 210000002845 virion Anatomy 0.000 description 40
- 241000283973 Oryctolagus cuniculus Species 0.000 description 39
- 239000002773 nucleotide Substances 0.000 description 38
- 125000003729 nucleotide group Chemical group 0.000 description 38
- 101710125418 Major capsid protein Proteins 0.000 description 34
- 230000003053 immunization Effects 0.000 description 33
- 238000002649 immunization Methods 0.000 description 33
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 32
- 102100034353 Integrase Human genes 0.000 description 31
- 229960005486 vaccine Drugs 0.000 description 31
- 210000002966 serum Anatomy 0.000 description 26
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 25
- 239000002953 phosphate buffered saline Substances 0.000 description 25
- 238000003556 assay Methods 0.000 description 24
- 239000013600 plasmid vector Substances 0.000 description 24
- 238000001262 western blot Methods 0.000 description 23
- 230000028993 immune response Effects 0.000 description 22
- 238000001493 electron microscopy Methods 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 20
- 239000012634 fragment Substances 0.000 description 19
- 238000013459 approach Methods 0.000 description 18
- 239000003623 enhancer Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 238000003156 radioimmunoprecipitation Methods 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 17
- 206010046865 Vaccinia virus infection Diseases 0.000 description 16
- 230000009257 reactivity Effects 0.000 description 16
- 208000007089 vaccinia Diseases 0.000 description 16
- 208000037357 HIV infectious disease Diseases 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N furocoumarin Natural products C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 15
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 15
- 239000002243 precursor Substances 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 230000003472 neutralizing effect Effects 0.000 description 14
- 239000008188 pellet Substances 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 13
- 239000013592 cell lysate Substances 0.000 description 13
- 239000000499 gel Substances 0.000 description 13
- 230000005847 immunogenicity Effects 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 11
- 101710121417 Envelope glycoprotein Proteins 0.000 description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 11
- 229930006000 Sucrose Natural products 0.000 description 11
- 230000024932 T cell mediated immunity Effects 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000005720 sucrose Substances 0.000 description 11
- 239000000020 Nitrocellulose Substances 0.000 description 10
- 238000010276 construction Methods 0.000 description 10
- 239000012228 culture supernatant Substances 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 229920001220 nitrocellulos Polymers 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 241000283707 Capra Species 0.000 description 9
- 101710150344 Protein Rev Proteins 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 9
- 230000034303 cell budding Effects 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000012894 fetal calf serum Substances 0.000 description 8
- 108091006104 gene-regulatory proteins Proteins 0.000 description 8
- 102000034356 gene-regulatory proteins Human genes 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000002458 infectious effect Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000006798 recombination Effects 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 7
- 241000701022 Cytomegalovirus Species 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 7
- 230000000840 anti-viral effect Effects 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000028996 humoral immune response Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 241000282552 Chlorocebus aethiops Species 0.000 description 6
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 6
- 241000282553 Macaca Species 0.000 description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 108010067390 Viral Proteins Proteins 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 238000000376 autoradiography Methods 0.000 description 6
- 230000000120 cytopathologic effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 108010041397 CD4 Antigens Proteins 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 5
- 108700002232 Immediate-Early Genes Proteins 0.000 description 5
- 108020005067 RNA Splice Sites Proteins 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000012761 co-transfection Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000000877 morphologic effect Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 102000013415 peroxidase activity proteins Human genes 0.000 description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 102000000844 Cell Surface Receptors Human genes 0.000 description 4
- 108700010908 HIV-1 proteins Proteins 0.000 description 4
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 108700005075 Regulator Genes Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000036436 anti-hiv Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 230000001566 pro-viral effect Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 108700004030 rev Genes Proteins 0.000 description 4
- 238000005199 ultracentrifugation Methods 0.000 description 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 108700025685 HIV Enhancer Proteins 0.000 description 3
- 229940033330 HIV vaccine Drugs 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 108020005038 Terminator Codon Proteins 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000635 electron micrograph Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229940031689 heterologous vaccine Drugs 0.000 description 3
- 238000000703 high-speed centrifugation Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 230000001589 lymphoproliferative effect Effects 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000007918 pathogenicity Effects 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000006337 proteolytic cleavage Effects 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 108700004027 tat Genes Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 230000010415 tropism Effects 0.000 description 3
- 210000003501 vero cell Anatomy 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 2
- 229940124718 AIDS vaccine Drugs 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 101100508409 Caenorhabditis elegans ifa-4 gene Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 229940033332 HIV-1 vaccine Drugs 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 108010023244 Lactoperoxidase Proteins 0.000 description 2
- 102000045576 Lactoperoxidases Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 2
- 101900209501 Vaccinia virus Thymidine kinase Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000000211 autoradiogram Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000007711 cytoplasmic localization Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940009976 deoxycholate Drugs 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229960000555 fenyramidol Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 101150047047 gag-pol gene Proteins 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 210000004201 immune sera Anatomy 0.000 description 2
- 229940042743 immune sera Drugs 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 229940057428 lactoperoxidase Drugs 0.000 description 2
- 238000000464 low-speed centrifugation Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000011236 particulate material Substances 0.000 description 2
- 108700004029 pol Genes Proteins 0.000 description 2
- 101150088264 pol gene Proteins 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 101150098213 rev gene Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 229940083538 smallpox vaccine Drugs 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000010246 ultrastructural analysis Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- 230000029302 virus maturation Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- 108700026758 Adenovirus hexon capsid Proteins 0.000 description 1
- 241000478345 Afer Species 0.000 description 1
- OGUPCHKBOKJFMA-SRVKXCTJSA-N Arg-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N OGUPCHKBOKJFMA-SRVKXCTJSA-N 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 101150075764 CD4 gene Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- YLJHCWNDBKKOEB-IHRRRGAJSA-N Glu-Glu-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O YLJHCWNDBKKOEB-IHRRRGAJSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 239000007756 Ham's F12 Nutrient Mixture Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 101800001892 Mature core protein Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000364057 Peoria Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010037213 Psychomotor retardation Diseases 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000676 anti-immunogenic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000025698 brain inflammatory disease Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000021040 cytoplasmic transport Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010218 electron microscopic analysis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003126 immunogold labeling Methods 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 108700004028 nef Genes Proteins 0.000 description 1
- 101150023385 nef gene Proteins 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 101150101054 tar gene Proteins 0.000 description 1
- 101150098170 tat gene Proteins 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 101150059019 vif gene Proteins 0.000 description 1
- 230000010464 virion assembly Effects 0.000 description 1
- 230000010463 virion release Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 108700026215 vpr Genes Proteins 0.000 description 1
- 101150024249 vpr gene Proteins 0.000 description 1
- 108700026222 vpu Genes Proteins 0.000 description 1
- 101150090490 vpu gene Proteins 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43920589A | 1989-11-20 | 1989-11-20 | |
| US439205 | 1999-11-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6905591A AU6905591A (en) | 1991-06-13 |
| AU636944B2 true AU636944B2 (en) | 1993-05-13 |
Family
ID=23743729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU69055/91A Ceased AU636944B2 (en) | 1989-11-20 | 1990-11-20 | Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0502105A4 (fi) |
| JP (1) | JPH05503629A (fi) |
| KR (1) | KR920703639A (fi) |
| AU (1) | AU636944B2 (fi) |
| CA (1) | CA2068713A1 (fi) |
| ES (1) | ES2052478T1 (fi) |
| FI (1) | FI922277A0 (fi) |
| GR (1) | GR930300005T1 (fi) |
| HU (1) | HUT60506A (fi) |
| NO (1) | NO921969L (fi) |
| OA (1) | OA09698A (fi) |
| TW (1) | TW216446B (fi) |
| WO (1) | WO1991007425A1 (fi) |
| ZA (1) | ZA909302B (fi) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU644535B2 (en) * | 1991-07-26 | 1993-12-09 | Basf Aktiengesellschaft | Aqueous polymer dispersions |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3034025B2 (ja) * | 1989-06-01 | 2000-04-17 | アプライド・バイオテクノロジー・インコーポレーテツド | 自己アセンブルド欠損非自己増殖性ウイルス粒子 |
| US5861282A (en) * | 1989-10-16 | 1999-01-19 | Whitehead Institute For Biomedical Research | Non-infectious HIV particles and uses therefor |
| WO1991019803A1 (en) * | 1990-06-19 | 1991-12-26 | Applied Biotechnology, Incorporated | Self assembled, defective, nonself-propagating viral particles |
| ES2177530T3 (es) * | 1991-11-08 | 2002-12-16 | Upjohn Co | Vacunas contra el virus de la leucemia felina. |
| AU2462392A (en) * | 1992-04-14 | 1993-11-18 | British Biotech Pharmaceuticals Limited | Induction of CTL responses |
| US7001759B1 (en) | 1993-01-26 | 2006-02-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| EP1473369B1 (en) | 1993-01-26 | 2009-01-07 | The Trustees of the University of Pennsylvania (a corporation of Pennsylvania) | Compositions and methods for delivery of genetic material |
| WO1994016737A1 (en) | 1993-01-26 | 1994-08-04 | Weiner David B | Compositions and methods for delivery of genetic material |
| GB9304239D0 (en) * | 1993-03-01 | 1993-04-21 | British Bio Technology | Viral particles |
| US5955342A (en) * | 1994-08-15 | 1999-09-21 | Connaught Laboratories Limited | Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region |
| US6291157B1 (en) | 1998-02-23 | 2001-09-18 | Connaught Laboratories Limited | Antigenically-marked non-infectious retrovirus-like particles |
| US5858838A (en) | 1998-02-23 | 1999-01-12 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method for increasing DRAM capacitance via use of a roughened surface bottom capacitor plate |
| US6080408A (en) | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
| WO1996030523A2 (en) * | 1995-03-31 | 1996-10-03 | Hans Wolf | Antigen presentation system based on retrovirus-like particles |
| US6013506A (en) * | 1995-06-05 | 2000-01-11 | Wardley; Richard C. | Feline leukemia virus vaccines |
| US6121021A (en) * | 1997-12-16 | 2000-09-19 | Connaught Laboratories Limited | Constitutive expression of non-infectious HIV-like particles |
| DE69938062T2 (de) | 1998-12-31 | 2009-01-15 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Modifizierte hiv env polypeptide |
| JP2003523721A (ja) | 1998-12-31 | 2003-08-12 | カイロン コーポレイション | 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用 |
| US8623379B2 (en) | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
| CA2401974C (en) | 2000-03-02 | 2013-07-02 | Emory University | Dna expression vectors and methods of use |
| DE60234018D1 (de) * | 2001-03-08 | 2009-11-26 | Univ Emory | Mva-exprimierende modifizierte hiv-envelope-, gag-, und pol-gene |
| AU2002320314A1 (en) | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| US9839684B2 (en) | 2011-04-06 | 2017-12-12 | Biovaxim Limited | Pharmaceutical compositions comprising inactivated HIV viral particles and non-pathogenic lactobacilli for the induction of antigen-specific immunotolerance |
| WO2017015463A2 (en) | 2015-07-21 | 2017-01-26 | Modernatx, Inc. | Infectious disease vaccines |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
| EP3938379A4 (en) * | 2019-03-15 | 2023-02-22 | ModernaTX, Inc. | HIV RNA VACCINE |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4752565A (en) * | 1986-04-07 | 1988-06-21 | The United States Of America As Represented By The Department Of Health And Human Services | Cell line producing AIDS viral antigens without producing infectious virus particles |
| JPH02203783A (ja) * | 1989-02-02 | 1990-08-13 | Banyu Pharmaceut Co Ltd | 抗原性を有する非感染性エイズウイルス産生クローン化ヒトｔ細胞 |
| JP3140757B2 (ja) * | 1989-02-06 | 2001-03-05 | デイナ・フアーバー・キヤンサー・インステイテユート | パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用 |
| GB8923123D0 (en) * | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| EP0496794A1 (en) * | 1989-10-16 | 1992-08-05 | Whitehead Institute For Biomedical Research | Non-infectious hiv-1 particles and uses therefor |
-
1990
- 1990-11-20 KR KR1019920701189A patent/KR920703639A/ko not_active Application Discontinuation
- 1990-11-20 ES ES91900526T patent/ES2052478T1/es active Pending
- 1990-11-20 EP EP19910900526 patent/EP0502105A4/en not_active Withdrawn
- 1990-11-20 JP JP3501082A patent/JPH05503629A/ja active Pending
- 1990-11-20 HU HU9201659A patent/HUT60506A/hu unknown
- 1990-11-20 ZA ZA909302A patent/ZA909302B/xx unknown
- 1990-11-20 WO PCT/US1990/006798 patent/WO1991007425A1/en not_active Application Discontinuation
- 1990-11-20 CA CA002068713A patent/CA2068713A1/en not_active Abandoned
- 1990-11-20 AU AU69055/91A patent/AU636944B2/en not_active Ceased
-
1991
- 1991-01-12 TW TW080100246A patent/TW216446B/zh active
-
1992
- 1992-05-19 OA OA60209A patent/OA09698A/en unknown
- 1992-05-19 FI FI922277A patent/FI922277A0/fi not_active Application Discontinuation
- 1992-05-19 NO NO92921969A patent/NO921969L/no unknown
-
1993
- 1993-04-28 GR GR930300005T patent/GR930300005T1/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU644535B2 (en) * | 1991-07-26 | 1993-12-09 | Basf Aktiengesellschaft | Aqueous polymer dispersions |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0502105A1 (en) | 1992-09-09 |
| WO1991007425A1 (en) | 1991-05-30 |
| ZA909302B (en) | 1991-09-25 |
| CA2068713A1 (en) | 1991-05-21 |
| ES2052478T1 (es) | 1994-07-16 |
| FI922277A (fi) | 1992-05-19 |
| GR930300005T1 (fi) | 1993-04-28 |
| EP0502105A4 (en) | 1993-02-24 |
| OA09698A (en) | 1993-08-30 |
| TW216446B (fi) | 1993-11-21 |
| FI922277A0 (fi) | 1992-05-19 |
| AU6905591A (en) | 1991-06-13 |
| KR920703639A (ko) | 1992-12-18 |
| NO921969D0 (no) | 1992-05-19 |
| HUT60506A (en) | 1992-09-28 |
| NO921969L (no) | 1992-06-26 |
| HU9201659D0 (en) | 1992-08-28 |
| JPH05503629A (ja) | 1993-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU636944B2 (en) | Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens | |
| JP3967374B2 (ja) | 同調的インビボ遺伝子発現 | |
| Stott et al. | Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine | |
| Hanke et al. | DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice | |
| JP6165612B2 (ja) | コンセンサス／先祖免疫原 | |
| Lu et al. | Simian immunodeficiency virus DNA vaccine trial in macaques | |
| Rusche et al. | Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells. | |
| Griffiths et al. | Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag: V3 fusion | |
| Giavedoni et al. | Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection | |
| Rovinski et al. | Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine | |
| GB2181435A (en) | Vaccines and immunoassays for acquired immune deficiency syndrome | |
| Ahmad et al. | Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus | |
| WO1996006177A2 (en) | Retrovirus-like particles made non-infectious by a plurality of mutations | |
| Winter et al. | Recombinant BCG strains expressing the SIVmac251nef gene induce proliferative and CTL responses against nef synthetic peptides in mice | |
| JP2000506727A (ja) | 組換え生ネコ免疫不全ウイルスおよびプロウイルスｄｎａワクチン | |
| Schlienger et al. | Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates | |
| Notka et al. | Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies | |
| WO1997005242A1 (en) | Novel replication competent human immunodeficiency virus type 2 (hiv-2) proviral clone designated hiv-2kr | |
| HAYNES et al. | Production of immunogenic HIV-1 viruslike particles in stably engineered monkey cell lines | |
| VAN EENDENBURG et al. | Cell-mediated immune proliferative responses to HIV-1 of chimpanzees vaccinated with different vaccinia recombinant viruses | |
| WO1991013906A1 (en) | PURIFIED gp120 COMPOSITION RETAINING NATURAL CONFORMATION | |
| IE904161A1 (en) | Nonreplicating recombinant-made retroviral particles useful¹as anti-viral agents and as immunogens for prophylaxis and¹therapy against human retroviruses | |
| Mills et al. | Vaccine-induced CD4+ T cells against the simian immunodeficiency virus gag protein. Epitope specificity and relevance to protective immunity. | |
| Schlienger et al. | Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge | |
| Notka et al. | Construction and characterization of recombinant VLPs and Semliki-Forest virus live vectors for comparative evaluation in the SHIV monkey model |